Related references
Note: Only part of the references are listed.Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
Tianling Ou et al.
PLOS PATHOGENS (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Victor M. Corman et al.
EUROSURVEILLANCE (2020)
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Peter Richardson et al.
LANCET (2020)
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen et al.
LANCET (2020)
COVID-19: combining antiviral and anti-inflammatory treatments
Justin Stebbing et al.
LANCET INFECTIOUS DISEASES (2020)
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Canrong Wu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Vanessa Monteil et al.
CELL (2020)
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
Jacques Fantini et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Yung-Fang Tu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Xiuyuan Ou et al.
NATURE COMMUNICATIONS (2020)
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
Jia Liu et al.
CELL DISCOVERY (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Leon Caly et al.
ANTIVIRAL RESEARCH (2020)
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Samia Arshad et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
Abdo A. Elfiky
LIFE SCIENCES (2020)
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Brandi N. Williamson et al.
NATURE (2020)
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Laura Riva et al.
NATURE (2020)
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse et al.
NATURE (2020)
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
A. B. Cavalcanti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
David R. Boulware et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Jerome Hadjadj et al.
SCIENCE (2020)
Potential Antiviral Options against SARS-CoV-2 Infection
Aleksandr Ianevski et al.
VIRUSES-BASEL (2020)
Profiling SARS-CoV-2 Main Protease (MPRO) Binding to Repurposed Drugs Using Molecular Dynamics Simulations in Classical and Neural Network-Trained Force Fields
Aayush Gupta et al.
ACS COMBINATORIAL SCIENCE (2020)
Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study
Brian Hanley et al.
LANCET MICROBE (2020)
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Zhiqi Song et al.
VIRUSES-BASEL (2019)
Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses
Jan Haviernik et al.
VIRUSES-BASEL (2018)
Ebola Virus and Severe Acute Respiratory Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence that Transport to NPC1+ Endolysosomes Is a Rate-Defining Step
Rebecca M. Mingo et al.
JOURNAL OF VIROLOGY (2015)
Development of novel entry inhibitors targeting emerging viruses
Yanchen Zhou et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2012)
Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain
Martha Schneider et al.
JOURNAL OF VIROLOGY (2012)
Fast gapped-read alignment with Bowtie 2
Ben Langmead et al.
NATURE METHODS (2012)
Azithromycin induces anti-viral responses in bronchial epithelial cells
V. Gielen et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Lipid rafts are involved in SARS-CoV entry into Vero E6 cells
Yanning Lu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
G Simmons et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
